🇪🇺 DS-1062a in European Union

DS-1062a (DS-1062a) regulatory status in European Union.

Marketing authorisation

EMA

  • Application: EMEA/H/C/006081
  • Marketing authorisation holder: Daiichi Sankyo Europe GmbH
  • Local brand name: Datopotamab deruxtecan Daiichi Sankyo
  • Indication: Treatment of adult patients with locally advanced or metastatic non squamous non-small cell lung cancer (NSCLC)
  • Status: withdrawn

Read official source →

Other Oncology approved in European Union

Frequently asked questions

Is DS-1062a approved in European Union?

Yes. EMA has authorised it.

Who is the marketing authorisation holder for DS-1062a in European Union?

Daiichi Sankyo Europe GmbH holds the EU marketing authorisation.